- Advertisement -
HomeWorldRDIF, Panacea Biotec. Has started production of Sputnik V vaccine in...

RDIF, Panacea Biotec. Has started production of Sputnik V vaccine in India.

- Advertisement -

Sputnik V vaccine in India: Sputnik V is the third vaccine given the Emergency Use Authority by the Indian drug regulator.

In a joint statement issued on May 24 by the Russian Direct Investment Fund (RDIF) and pharmaceutical firm Panacea Biotech, the production use of Sputnik V, the COVID-19 vaccine, has been granted emergency use authorization, which has been launched in India.

The statement said that the first batch of doses produced at Panacea Biotech facilities in Baddi, Himachal Pradesh, would be shipped to the Gamalaya Center in Moscow for “quality control”.

Full-scale production of the vaccine is due to begin this summer, stating that the company’s facilities “comply with GMP standards and are pre-qualified by WHO (World Health Organization)”.

Cyclone Yas Live Update: Deep depression subsides

in Bay of Bengal for 6 hours, NDRF made 46 teams before landfall

The Managing Director of Panacea Biotech, Dr. Rajesh Jain said that the production of Sputnik V is an important step in the fight against the virus in India. “With RDIF, we hope to help bring back a sense of normalcy to people around the country and the world,” he said. RDIF chief executive Kirill Dmitriev said domestic production of Sputnik V supports India’s efforts to “leave behind a” rapid phase of coronavirus as soon as possible “.


“The vaccine will be exported at a later stage to help prevent the spread of the virus to other countries around the world,” he said.

Sputnik V was registered in India on April 12, 2021 under the Emergency Use Authorization Procedure. As announced in April, RDIF and Panacea have agreed to produce 100 million doses per year of Sputnik V.

RDIF has also partnered with Hyderabad-based Dr Reddy’s Laboratories for local production and distribution of vaccines.

To date, Sputnik V has been registered in 66 countries with a total population of over 3.2 billion people. In Russia, the efficacy of Sputnik V is 97.6 percent, based on an analysis of data on coronavirus infection rates in those vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021.

The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for two shots during vaccination, “comparing vaccines using the same delivery mechanism for both shots Providing immunity with a longer duration of time “, the statement said.

Sputnik V is the third COVID-19 vaccine to be given to beneficiaries across India. The country has so far conducted its vaccination campaign using kovishield and covaxin manufactured by Pune-based Serum Institute of India and Hyderabad-based Bharat Biotech Limited.

- Advertisement -
- Advertisement -

Must Read

- Advertisement -

Related News

- Advertisement -